Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Human neutralizing antibodies against SARS-CoV-2 require intact Fc effector functions for optimal therapeutic protection
Emma S. Winkler, Pavlo Gilchuk, Jinsheng Yu, et al.
Cell (2021) Vol. 184, Iss. 7, pp. 1804-1820.e16
Open Access | Times Cited: 354

Showing 1-25 of 354 citing articles:

The biological and clinical significance of emerging SARS-CoV-2 variants
Kaiming Tao, Philip L. Tzou, Janin Nouhin, et al.
Nature Reviews Genetics (2021) Vol. 22, Iss. 12, pp. 757-773
Open Access | Times Cited: 993
Resistance of SARS-CoV-2 variants to neutralization by monoclonal and serum-derived polyclonal antibodies
Rita E. Chen, Xianwen Zhang, James Brett Case, et al.
Nature Medicine (2021) Vol. 27, Iss. 4, pp. 717-726
Open Access | Times Cited: 974
N-terminal domain antigenic mapping reveals a site of vulnerability for SARS-CoV-2
Matthew McCallum, Anna De Marco, Florian A. Lempp, et al.
Cell (2021) Vol. 184, Iss. 9, pp. 2332-2347.e16
Open Access | Times Cited: 950
An infectious SARS-CoV-2 B.1.1.529 Omicron virus escapes neutralization by therapeutic monoclonal antibodies
Laura A. VanBlargan, John M. Errico, Peter Halfmann, et al.
Nature Medicine (2022) Vol. 28, Iss. 3, pp. 490-495
Open Access | Times Cited: 716
SARS-CoV-2 Omicron virus causes attenuated disease in mice and hamsters
Peter Halfmann, Shun Iida, Kiyoko Iwatsuki‐Horimoto, et al.
Nature (2022) Vol. 603, Iss. 7902, pp. 687-692
Open Access | Times Cited: 599
SARS-CoV-2 RBD antibodies that maximize breadth and resistance to escape
Tyler N. Starr, Nadine Czudnochowski, Zhuoming Liu, et al.
Nature (2021) Vol. 597, Iss. 7874, pp. 97-102
Open Access | Times Cited: 506
After the pandemic: perspectives on the future trajectory of COVID-19
Amalio Telenti, Ann M. Arvin, Lawrence Corey, et al.
Nature (2021) Vol. 596, Iss. 7873, pp. 495-504
Open Access | Times Cited: 399
Tackling COVID-19 with neutralizing monoclonal antibodies
Davide Corti, Lisa A. Purcell, Gyorgy Snell, et al.
Cell (2021) Vol. 184, Iss. 12, pp. 3086-3108
Open Access | Times Cited: 373
Broad betacoronavirus neutralization by a stem helix–specific human antibody
Dora Pinto, Maximilian M. Sauer, Nadine Czudnochowski, et al.
Science (2021) Vol. 373, Iss. 6559, pp. 1109-1116
Open Access | Times Cited: 361
Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
Obbina Abani, Ali Abbas, Fatima Abbas, et al.
The Lancet (2022) Vol. 399, Iss. 10325, pp. 665-676
Open Access | Times Cited: 358
Distinguishing features of current COVID-19 vaccines: knowns and unknowns of antigen presentation and modes of action
Franz X. Heinz, Karin Stiasny
npj Vaccines (2021) Vol. 6, Iss. 1
Open Access | Times Cited: 348
Broad sarbecovirus neutralization by a human monoclonal antibody
M. Alejandra Tortorici, Nadine Czudnochowski, Tyler N. Starr, et al.
Nature (2021) Vol. 597, Iss. 7874, pp. 103-108
Open Access | Times Cited: 276
Prospects for durable immune control of SARS-CoV-2 and prevention of reinfection
Deborah Cromer, Jennifer A. Juno, David S. Khoury, et al.
Nature reviews. Immunology (2021) Vol. 21, Iss. 6, pp. 395-404
Open Access | Times Cited: 260
In vivo monoclonal antibody efficacy against SARS-CoV-2 variant strains
Rita E. Chen, Emma S. Winkler, James Brett Case, et al.
Nature (2021) Vol. 596, Iss. 7870, pp. 103-108
Open Access | Times Cited: 252
Convalescent plasma for hospitalized patients with COVID-19: an open-label, randomized controlled trial
Philippe Bégin, Jeannie Callum, Erin Jamula, et al.
Nature Medicine (2021) Vol. 27, Iss. 11, pp. 2012-2024
Open Access | Times Cited: 246
Correlates of protection against SARS‐CoV‐2 infection and COVID‐19 disease
David Goldblatt, Galit Alter, Shane Crotty, et al.
Immunological Reviews (2022) Vol. 310, Iss. 1, pp. 6-26
Open Access | Times Cited: 244
Infection- and vaccine-induced antibody binding and neutralization of the B.1.351 SARS-CoV-2 variant
Venkata Viswanadh Edara, Carson Norwood, Katharine Floyd, et al.
Cell Host & Microbe (2021) Vol. 29, Iss. 4, pp. 516-521.e3
Open Access | Times Cited: 236
Drug repurposing screens reveal cell-type-specific entry pathways and FDA-approved drugs active against SARS-Cov-2
Mark Dittmar, Jae Seung Lee, Kanupriya Whig, et al.
Cell Reports (2021) Vol. 35, Iss. 1, pp. 108959-108959
Open Access | Times Cited: 226
High titers and low fucosylation of early human anti–SARS-CoV-2 IgG promote inflammation by alveolar macrophages
Willianne Hoepel, Hung‐Jen Chen, Chiara E. Geyer, et al.
Science Translational Medicine (2021) Vol. 13, Iss. 596
Open Access | Times Cited: 218
Live imaging of SARS-CoV-2 infection in mice reveals that neutralizing antibodies require Fc function for optimal efficacy
Irfan Ullah, Jérémie Prévost, Mark S. Ladinsky, et al.
Immunity (2021) Vol. 54, Iss. 9, pp. 2143-2158.e15
Open Access | Times Cited: 199
SARS-CoV-2 breakthrough infections elicit potent, broad, and durable neutralizing antibody responses
Alexandra C. Walls, Kaitlin R. Sprouse, John E. Bowen, et al.
Cell (2022) Vol. 185, Iss. 5, pp. 872-880.e3
Open Access | Times Cited: 198
The SARS-CoV-2 monoclonal antibody combination, AZD7442, is protective in nonhuman primates and has an extended half-life in humans
Yueh–Ming Loo, Patrick M. McTamney, Rosalinda H. Arends, et al.
Science Translational Medicine (2022) Vol. 14, Iss. 635
Open Access | Times Cited: 194
Fc-engineered antibody therapeutics with improved anti-SARS-CoV-2 efficacy
Rachel Yamin, Andrew Jones, Hans-Heinrich Hoffmann, et al.
Nature (2021) Vol. 599, Iss. 7885, pp. 465-470
Open Access | Times Cited: 166
Antibodies to combat viral infections: development strategies and progress
Giuseppe Pantaleo, Bruno E. Correia, Craig Fenwick, et al.
Nature Reviews Drug Discovery (2022) Vol. 21, Iss. 9, pp. 676-696
Open Access | Times Cited: 158
Defining the risk of SARS-CoV-2 variants on immune protection
Marciela M. DeGrace, Elodie Ghedin, Matthew B. Frieman, et al.
Nature (2022) Vol. 605, Iss. 7911, pp. 640-652
Open Access | Times Cited: 154
Page 1 - Next Page

Scroll to top